Partners

Dynavax has partnerships with major pharmaceutical companies and funding agreements to support our discovery and development programs. These agreements include:

Our TLR inhibitor therapies are partnered under a worldwide strategic alliance with GlaxoSmithKline, one of the world’s leading research-based pharmaceutical and healthcare companies.

Our asthma/COPD therapies are partnered under a global agreement with AstraZeneca, an industry leader in products for respiratory diseases.

Our Universal Flu vaccine is under a global supply and option agreement with Novartis, a leader in influenza vaccines.